Vanderbilt University Medical Center (VUMC)

September 19, 2022

Study investigator Jeffrey L. Neul, MD, PhD, offered his perspective on the current understanding of trofinetide (Acadia Pharmaceuticals) and its potential in Rett syndrome if approved by the FDA in the coming months.

September 12, 2022

The treatment, previously known as NNZ-2566, is supported by data from the LAVENDER study. With no plans to hold an advisory meeting, the agency set a PDUFA date of March 12, 2023, for the Acadia Pharmaceuticals product.

July 12, 2022

The risk of developing Alzheimer disease and related dementias decreased gradually with increasing scores in a dose-response manner on a model geared toward identifying healthy lifestyle factors.

February 04, 2022

The assistant clinical professor at Vanderbilt University School of Medicine discussed ways of incorporating and encouraging women physicians to enter the neurology specialty. [WATCH TIME: 4 minutes]

February 03, 2022

The assistant clinical professor at Vanderbilt University School of Medicine shared what National Women Physicians Day means to her, and the history behind its celebration. [WATCH TIME: 6 minutes]

January 30, 2022

After discontinuing dosing in the phase 3 GENERATION HD1 study in 2021, Roche is designing a new phase 2 trial for tominersen, its investigational antisense oligomer for Huntington disease.